Aligos Therapeutics receives USD 25 million upfront from Greater China pevifoscorvir license deal

Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc.

ALGS

0.00
  • Aligos received an upfront payment of USD 25 million from an exclusive Greater China license for pevifoscorvir sodium in chronic hepatitis B.
  • Deal terms include up to USD 420 million in clinical, regulatory, sales milestones; tiered high single-digit royalties on net sales.
  • China’s NMPA drug regulator granted Breakthrough Therapy Designation, enabling eligibility for priority NDA review.
  • Aligos retains development and commercialization rights outside Greater China, including the US and Europe.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aligos Therapeutics Inc. published the original content used to generate this news brief on July 06, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.